Related references
Note: Only part of the references are listed.Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
Steven A. Lacy et al.
CLINICAL PHARMACOKINETICS (2017)
The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance
Katarzyna Miekus
ONCOLOGY REPORTS (2017)
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
I. Duran et al.
TARGETED ONCOLOGY (2017)
MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
Stephan Macher-Goeppinger et al.
ONCOTARGET (2017)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review
Jung Han Kim et al.
ONCOTARGET (2017)
Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib
Katriina Johanna Peltola et al.
CLINICAL GENITOURINARY CANCER (2017)
Understanding c-MET signalling in squamous cell carcinoma of the head & neck
P. Szturz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Sebastian Bender et al.
NATURE MEDICINE (2016)
Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
Boram Kim et al.
PHYTOTHERAPY RESEARCH (2016)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
MET receptor is a potential therapeutic target in high grade cervical cancer
Katarzyna Miekus et al.
ONCOTARGET (2015)
Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression
Klaudia Skrzypek et al.
ONCOTARGET (2015)
MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
Brian Shuch et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Remi Adelaiye et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
Eric Ciamporcero et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis
Shoichiro Mukai et al.
HUMAN CELL (2015)
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2014)
Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Zofia Bielecka et al.
Current Signal Transduction Therapy (2014)
Evolution of acquired resistance to anti-cancer therapy
Jasmine Foo et al.
JOURNAL OF THEORETICAL BIOLOGY (2014)
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Erinn B. Rankin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
G. T. Gibney et al.
ANNALS OF ONCOLOGY (2013)
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Omid Hamid et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells
Atsushi Matsumura et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation
K. Miekus et al.
CELL DEATH & DISEASE (2013)
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Barbara Sennino et al.
CANCER DISCOVERY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
Pankaj Bhargava et al.
CURRENT ONCOLOGY REPORTS (2011)
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Farbod Shojaei et al.
CANCER RESEARCH (2010)
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
J. Rafael Sierra et al.
MOLECULAR CANCER (2010)
Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
Hans J. Hammers et al.
MOLECULAR CANCER THERAPEUTICS (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?
Elizabeth Charytonowicz et al.
CANCER LETTERS (2009)
VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma
W. Marston Linehan et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Resistance to targeted therapy in renal-cell carcinoma
Brian I. Rini et al.
LANCET ONCOLOGY (2009)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Prognostic factors in a prospective series of papillary renal cell carcinoma
Paolo Gontero et al.
BJU INTERNATIONAL (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Epithelial-mesenchymal transition in cervical cancer: Correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation
Mei-Yi Lee et al.
CLINICAL CANCER RESEARCH (2008)
Expression and Mutational Analysis of MET in Human Solid Cancers
Patrick C. Ma et al.
GENES CHROMOSOMES & CANCER (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma
Hironori Betsunoh et al.
CANCER SCIENCE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma
Yasuyoshi Miyata et al.
CLINICAL CANCER RESEARCH (2006)
MET expression in sporadic renal cell carcinomas
Jong Sun Choi et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2006)
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma
Riccardo Taulli et al.
CANCER RESEARCH (2006)
Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma
N Nakaigawa et al.
CANCER RESEARCH (2006)
Complex networks orchestrate epithelial-mesenchymal transitions
JP Thiery et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
SE Witta et al.
CANCER RESEARCH (2006)
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair
CG Huh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions:: a comparison with Snail and E47 repressors
V Bolós et al.
JOURNAL OF CELL SCIENCE (2003)
Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development
D Shook et al.
MECHANISMS OF DEVELOPMENT (2003)
Renal tumors in the Birt-Hogg-Dube syndrome
CP Pavlovich et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Biological significance of c-met over expression in papillary renal cell carcinoma
P Sweeney et al.
JOURNAL OF UROLOGY (2002)
Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway
R Paumelle et al.
ONCOGENE (2002)
Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas
RR Oh et al.
APMIS (2002)
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase
KA Furge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Vasculogenic mimicry and tumor angiogenesis
R Folberg et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
